- Home
- MBWM vs INBX Comparison
MBWM vs INBX Comparison
Compare MBWM & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MBWM | INBX |
|---|---|---|
| Founded | 1997 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 862.3M | 999.7M |
| IPO Year | 1997 | 2024 |
Fundamental Metrics
Financial Performance| Metric | MBWM | INBX |
|---|---|---|
| Price | $49.40 | $58.33 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | ★ $53.63 | N/A |
| AVG Volume (30 Days) | 94.7K | ★ 143.2K |
| Earning Date | 04-21-2026 | 03-19-2026 |
| Dividend Yield | ★ 3.13% | N/A |
| EPS Growth | ★ 10.95 | N/A |
| EPS | ★ 5.47 | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | $20.28 | N/A |
| Revenue Next Year | $4.67 | N/A |
| P/E Ratio | $9.10 | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $37.76 | $10.81 |
| 52 Week High | $55.77 | $94.57 |
Technical Indicators
Market Signals| Indicator | MBWM | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 41.58 | 33.28 |
| Support Level | $47.78 | $28.54 |
| Resistance Level | $50.36 | $85.97 |
| Average True Range (ATR) | 1.35 | 4.27 |
| MACD | -0.03 | -0.55 |
| Stochastic Oscillator | 27.61 | 8.45 |
Price Performance
Historical ComparisonAbout MBWM Mercantile Bank Corporation
Mercantile Bank Corp operates as a bank holding company. It offers various commercial banking services to individuals, businesses, governmental units, and other institutions. These services include deposit products such as checking, savings, and term certificate accounts and lending products such as commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.